Yixintang Pharmaceutical Group Co., Ltd.
Symbol: 002727.SZ
SHZ
18.75
CNYMarktpreis heute
23.9311
P/E-Verhältnis
0.6980
PEG-Verhältnis
11.17B
MRK Kapital
- 0.02%
DIV Rendite
Yixintang Pharmaceutical Group Co., Ltd. (002727-SZ) Finanzberichte
Bilanz
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
balance-sheet.row.cash-and-short-term-investments | 0 | 3895.3 | 3520 | 2532.4 | |||||||||||||||
balance-sheet.row.short-term-investments | 0 | 219.7 | 8.4 | 297.3 | |||||||||||||||
balance-sheet.row.net-receivables | 0 | 1991.7 | 2411 | 1777.5 | |||||||||||||||
balance-sheet.row.inventory | 0 | 3852.6 | 3387.4 | 3317 | |||||||||||||||
balance-sheet.row.other-current-assets | 0 | 153.3 | 139.2 | 65.5 | |||||||||||||||
balance-sheet.row.total-current-assets | 0 | 9892.9 | 9457.6 | 7692.4 | |||||||||||||||
balance-sheet.row.property-plant-equipment-net | 0 | 3995.6 | 3993.5 | 4080 | |||||||||||||||
balance-sheet.row.goodwill | 0 | 1649.6 | 1397.2 | 1380 | |||||||||||||||
balance-sheet.row.intangible-assets | 0 | 184.1 | 165.7 | 122.9 | |||||||||||||||
balance-sheet.row.goodwill-and-intangible-assets | 0 | 1833.7 | 1562.9 | 1502.8 | |||||||||||||||
balance-sheet.row.long-term-investments | 0 | 165.3 | 131.4 | -190.1 | |||||||||||||||
balance-sheet.row.tax-assets | 0 | 88.9 | 94.1 | 58.5 | |||||||||||||||
balance-sheet.row.other-non-current-assets | 0 | 670.8 | 939.5 | 1193.8 | |||||||||||||||
balance-sheet.row.total-non-current-assets | 0 | 6754.5 | 6721.5 | 6645 | |||||||||||||||
balance-sheet.row.other-assets | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.total-assets | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.account-payables | 0 | 2560.2 | 4328.8 | 3805.9 | |||||||||||||||
balance-sheet.row.short-term-debt | 0 | 3333.9 | 1335.5 | 1143.9 | |||||||||||||||
balance-sheet.row.tax-payables | 0 | 81.4 | 250.4 | 164.1 | |||||||||||||||
balance-sheet.row.long-term-debt-total | 0 | 1552.2 | 1758.5 | 1764.1 | |||||||||||||||
Deferred Revenue Non Current | 0 | 1.2 | 12.2 | 13.3 | |||||||||||||||
balance-sheet.row.deferred-tax-liabilities-non-current | 0 | - | - | - | |||||||||||||||
balance-sheet.row.other-current-liab | 0 | 1191.9 | 1055.8 | 12.7 | |||||||||||||||
balance-sheet.row.total-non-current-liabilities | 0 | 1557.3 | 1774.7 | 1781 | |||||||||||||||
balance-sheet.row.other-liabilities | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.capital-lease-obligations | 0 | 1552.2 | 1756.7 | 1729 | |||||||||||||||
balance-sheet.row.total-liab | 0 | 8757.1 | 8651.5 | 7664.8 | |||||||||||||||
balance-sheet.row.preferred-stock | 0 | 0 | 0 | 0 | |||||||||||||||
balance-sheet.row.common-stock | 0 | 596 | 596 | 596.2 | |||||||||||||||
balance-sheet.row.retained-earnings | 0 | 4646.4 | 4335.4 | 3504.2 | |||||||||||||||
balance-sheet.row.accumulated-other-comprehensive-income-loss | 0 | 377.8 | 424.9 | 405.6 | |||||||||||||||
balance-sheet.row.other-total-stockholders-equity | 0 | 2125.8 | 2069.8 | 2071.7 | |||||||||||||||
balance-sheet.row.total-stockholders-equity | 0 | 7746 | 7426.1 | 6577.7 | |||||||||||||||
balance-sheet.row.total-liabilities-and-stockholders-equity | 0 | 16647.4 | 16179.1 | 14337.3 | |||||||||||||||
balance-sheet.row.minority-interest | 0 | 131 | 101.4 | 94.8 | |||||||||||||||
balance-sheet.row.total-equity | 0 | 7877 | 7527.6 | 6672.5 | |||||||||||||||
balance-sheet.row.total-liabilities-and-total-equity | 0 | - | - | - | |||||||||||||||
Total Investments | 0 | 385 | 139.8 | 107.2 | |||||||||||||||
balance-sheet.row.total-debt | 0 | 4886.1 | 3094 | 2908 | |||||||||||||||
balance-sheet.row.net-debt | 0 | 1210.5 | -417.6 | 672.9 |
Kapitalflussrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
cash-flows.row.net-income | 0 | 549.4 | 1013 | 917.2 | |||||||||||||||
cash-flows.row.depreciation-and-amortization | 0 | 0 | 1000.6 | 1087.8 | |||||||||||||||
cash-flows.row.deferred-income-tax | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.stock-based-compensation | 0 | 0 | 14.2 | 40.4 | |||||||||||||||
cash-flows.row.change-in-working-capital | 0 | 0 | -9.7 | -603.9 | |||||||||||||||
cash-flows.row.account-receivables | 0 | 0 | -765.8 | -739.7 | |||||||||||||||
cash-flows.row.inventory | 0 | 0 | -234.9 | -1236.8 | |||||||||||||||
cash-flows.row.account-payables | 0 | 0 | 1026.1 | 1399.9 | |||||||||||||||
cash-flows.row.other-working-capital | 0 | 0 | -35.1 | -27.3 | |||||||||||||||
cash-flows.row.other-non-cash-items | 0 | -549.4 | 514.1 | 377.5 | |||||||||||||||
cash-flows.row.net-cash-provided-by-operating-activities | 0 | 0 | 0 | 0 | |||||||||||||||
cash-flows.row.investments-in-property-plant-an-equipment | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.acquisitions-net | 0 | 0 | -4.7 | -65.1 | |||||||||||||||
cash-flows.row.purchases-of-investments | 0 | 0 | -980.5 | -1976.5 | |||||||||||||||
cash-flows.row.sales-maturities-of-investments | 0 | 0 | 1207.2 | 2901.8 | |||||||||||||||
cash-flows.row.other-investing-activites | 0 | 0 | -94.7 | -336.9 | |||||||||||||||
cash-flows.row.net-cash-used-for-investing-activites | 0 | 0 | -221.7 | 131.7 | |||||||||||||||
cash-flows.row.debt-repayment | 0 | 0 | -207.9 | -137.1 | |||||||||||||||
cash-flows.row.common-stock-issued | 0 | 0 | 2 | 0.1 | |||||||||||||||
cash-flows.row.common-stock-repurchased | 0 | 0 | -2 | -0.1 | |||||||||||||||
cash-flows.row.dividends-paid | 0 | 0 | -191.6 | -180.9 | |||||||||||||||
cash-flows.row.other-financing-activites | 0 | 0 | -678.6 | -986.8 | |||||||||||||||
cash-flows.row.net-cash-used-provided-by-financing-activities | 0 | 0 | -1078.2 | -1304.8 | |||||||||||||||
cash-flows.row.effect-of-forex-changes-on-cash | 0 | 0 | 0.3 | -0.1 | |||||||||||||||
cash-flows.row.net-change-in-cash | 0 | 0 | 1197.5 | 618.5 | |||||||||||||||
cash-flows.row.cash-at-end-of-period | 0 | 2859.5 | 2859.5 | 1661.9 | |||||||||||||||
cash-flows.row.cash-at-beginning-of-period | 0 | 2859.5 | 1661.9 | 1043.5 | |||||||||||||||
cash-flows.row.operating-cash-flow | 0 | 0 | 2497.1 | 1791.7 | |||||||||||||||
cash-flows.row.capital-expenditure | 0 | 0 | -349 | -391.6 | |||||||||||||||
cash-flows.row.free-cash-flow | 0 | 0 | 2148.1 | 1400 |
Zeile der Gewinn- und Verlustrechnung
common:word.in-mln USD Growth | TTM | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
income-statement-row.row.total-revenue | 0 | 17301.4 | 17431.6 | 14587.4 | |||||||||||||||
income-statement-row.row.cost-of-revenue | 0 | 11750.3 | 11322.3 | 9196.5 | |||||||||||||||
income-statement-row.row.gross-profit | 0 | 5551 | 6109.3 | 5390.9 | |||||||||||||||
income-statement-row.row.gross-profit-ratio | 0 | 0 | 0 | 0 | |||||||||||||||
income-statement-row.row.research-development | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-general-administrative | 0 | - | - | - | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.operating-expenses | 0 | 4717.5 | 4496.8 | 4091.3 | |||||||||||||||
income-statement-row.row.cost-and-expenses | 0 | 16467.8 | 15819.1 | 13287.8 | |||||||||||||||
income-statement-row.row.interest-income | 0 | -77.6 | 53.4 | 39.2 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.selling-and-marketing-expenses | 0 | - | - | - | |||||||||||||||
income-statement-row.row.total-other-income-expensenet | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.ebitda-ratio-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.other-operating-expenses | 0 | -106.6 | 349.1 | 320.6 | |||||||||||||||
income-statement-row.row.total-operating-expenses | 0 | -123.6 | -426.9 | 28.6 | |||||||||||||||
income-statement-row.row.interest-expense | 0 | 135.3 | 147.1 | 136.2 | |||||||||||||||
income-statement-row.row.depreciation-and-amortization | 0 | 1332.4 | 1000.6 | 1397.7 | |||||||||||||||
income-statement-row.row.ebitda-caps | 0 | - | - | - | |||||||||||||||
income-statement-row.row.operating-income | 0 | 833.5 | 1661.9 | 1067.9 | |||||||||||||||
income-statement-row.row.income-before-tax | 0 | 709.9 | 1235 | 1096.5 | |||||||||||||||
income-statement-row.row.income-tax-expense | 0 | 142.2 | 222 | 179.3 | |||||||||||||||
income-statement-row.row.net-income | 0 | 549.4 | 1010 | 921.6 |
Häufig gestellte Frage
Wie hoch ist die Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Gesamtvermögen?
Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) Gesamtvermögen ist 16647375283.000.
Wie hoch ist der Jahresumsatz des Unternehmens?
Der Jahresumsatz ist N/A.
Wie hoch ist die Gewinnspanne des Unternehmens?
Die Gewinnmarge des Unternehmens ist 0.318.
Wie hoch ist der freie Cashflow des Unternehmens?
Der freie Cashflow ist 3.367.
Wie hoch ist die Nettogewinnspanne des Unternehmens?
Die Nettogewinnmarge ist 0.031.
Wie hoch sind die Gesamteinnahmen des Unternehmens?
Der Gesamtertrag ist 0.045.
Was ist der Yixintang Pharmaceutical Group Co., Ltd. (002727.SZ) nettogewinn (reingewinn)?
Der Nettogewinn (Nettoeinkommen) ist 549441525.000.
Wie hoch ist die Gesamtverschuldung des Unternehmens?
Die Gesamtverschuldung ist 4886107552.000.
Wie hoch ist der Betriebsaufwand?
Die Betriebsausgaben sind 4717493463.000.
Wie hoch ist der Bargeldbestand des Unternehmens?
Die Unternehmensliquidität ist 0.000.